M. Lacevic
Impact in
-
- Meta-analysis and systematic reviews
- Pharmacology top 2%
- Pharmaceutical industry and healthcare
Papers in
- Oncology 8
- Cancer Treatment and Pharmacology 5
-
- Histone Deacetylase Inhibitors Research 5
- Protein Degradation and Inhibitors 2
- Cancer therapeutics and mechanisms 2
- Co-authors
- Roohi Ismail‐Khan (5 shared papers)Pamela N. Münster (8 shared papers)Susan Minton (4 shared papers)Benjamin Djulbegović (2 shared papers)Jared Adams (2 shared papers)Gary H. Lyman (2 shared papers)Charles L. Bennett (1 shared paper)Nicole M. Kuderer (1 shared paper)
- Journals
- Journal of Clinical Oncology (7 papers)Cancer Research (2 papers)British Journal of Cancer (1 paper)Annals of Oncology (1 paper)The Lancet (1 paper)
- Partner nations
- United States
In The Last Decade
M. Lacevic
11 papers receiving 850 citations
Peers
Comparison fields: 5 of 100
- Statistics, Probability and Uncertainty 151
- Pharmacology 181
- Reproductive Medicine 151
- Medical Terminology 4
- Public Health, Environmental and Occupational Health 284
Countries citing papers authored by M. Lacevic
This map shows the geographic impact of M. Lacevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lacevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lacevic more than expected).
Fields of papers citing papers by M. Lacevic
This network shows the impact of papers produced by M. Lacevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lacevic. The network helps show where M. Lacevic may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Lacevic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 346 | |
| 2 | 2011 | 315 | |
| 3 | 2012 | 163 | |
| 4 | 2008 | 28 | |
| 5 | 2008 | 14 | |
| 6 | 2009 | 13 | |
| 7 | 2001 | 11 | |
| 8 | 2009 | 8 | |
| 9 | 2007 | 4 | |
| 10 | 2006 | 2 | |
| 11 | Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer. | 2006 | 1 |
| 12 | 2019 | 1 |
About M. Lacevic
M. Lacevic is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine, having authored 12 papers that have together received 906 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Histone Deacetylase Inhibitors Research (5 papers), Advanced Breast Cancer Therapies (3 papers), Protein Degradation and Inhibitors (2 papers), Cancer therapeutics and mechanisms (2 papers), Reproductive Biology and Fertility (2 papers), Lymphoma Diagnosis and Treatment (1 paper) and Breast Cancer Treatment Studies (1 paper). The work is most often cited by research in Statistics, Probability and Uncertainty (151 citations), Pharmacology (181 citations), Reproductive Medicine (151 citations), Medical Terminology (4 citations) and Public Health, Environmental and Occupational Health (284 citations). M. Lacevic has collaborated with scholars based in United States. Frequent co-authors include Roohi Ismail‐Khan, Pamela N. Münster, Susan Minton, Benjamin Djulbegović, Jared Adams, Gary H. Lyman, Charles L. Bennett, Nicole M. Kuderer, Alan Cantor and Karen K. Fields. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, British Journal of Cancer, Annals of Oncology and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.